

YOUR GUIDE TO



stemline arc[®]

access | reimbursement support | care

Stemline ARC[®]: Committed to helping you get the support you need

Once enrolled in Stemline ARC, you will receive ongoing support and care from dedicated Nurse Advocates throughout the course of your treatment.

Dedicated Nurse Advocates are available to provide education and answer questions about treatment with **ELZONRIS[®] (tagraxofusp-erzs) Injection for Intravenous (IV) Use**. Nurse Advocate support is not intended to replace discussions between you and your healthcare provider.

About ELZONRIS[®] (tagraxofusp-erzs)

ELZONRIS is a prescription medicine used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients 2 years and older.

IMPORTANT SAFETY INFORMATION

ELZONRIS can cause serious side effects, including:

- **Capillary Leak Syndrome (CLS)**. ELZONRIS can cause fluid to leak from small blood vessels into your body's tissues. This is called "Capillary Leak Syndrome." CLS can quickly cause you to have symptoms that may become life-threatening or fatal (ie, lead to death). **Get emergency medical help immediately if you develop any of the following symptoms:**
 - fast weight gain
 - swelling of your face, arms, hands, legs, or feet
 - shortness of breath or difficulty breathing
 - low blood pressure (dizziness or lightheadedness, headache, feeling tired, or shortness of breath)

Your healthcare provider will check your weight and test your blood before you receive each dose of ELZONRIS and as needed during treatment.

Stemline[®]

 **ELZONRIS[®]**
(tagraxofusp-erzs) Injection

Please see accompanying full Prescribing Information, including Boxed WARNING.

Stemline ARC: Help and Support When You Need It Most

You may be able to receive financial assistance through several support programs. Talk to your treatment team about which programs you may be eligible for.



Stemline Commercial Co-Pay Program*

- Eligible patients may pay as little as \$0 for ELZONRIS Injection for IV Use

Please see page 5 for the full terms and conditions.



Stemline Patient Assistance Program†

- The Stemline Patient Assistance Program provides ELZONRIS Injection for IV Use to eligible patients who are under- or uninsured. Patients must meet certain criteria to qualify

Call 1-833-4-STEMLINE (1-833-478-3654) for more information.



Independent Third-Party Foundations‡

- Stemline ARC can provide information about independent third-party foundations

Before you enroll in Stemline ARC, talk to your doctor about which documents you may need, and remember to sign all required forms.

*Patients must meet eligibility criteria. In order to be eligible for the Stemline Commercial Co-Pay Program, the patient must not have government-funded health insurance (eg, Medicare, Medicaid, or any other federal or state program), must be taking ELZONRIS Injection for IV Use for an FDA-approved indication, and must confirm that they meet all of the eligibility criteria and agree to the rules set forth in the terms and conditions for the program. Patients and healthcare providers are responsible for completing and submitting enrollment forms and coverage or reimbursement documentation. Stemline Therapeutics, Inc. makes no representation or guarantee concerning coverage or reimbursement of any service or item.

†To be eligible for this program, insured patients must have exhausted all other forms of patient assistance and meet financial criteria. Insured and uninsured patients must also meet certain eligibility criteria.

‡Stemline Therapeutics, Inc. does not influence or control the operations or eligibility criteria of any independent charitable assistance foundation and cannot guarantee assistance after information has been provided by Stemline ARC. The information is provided as a resource to patients. The foundations that we discuss with patients are not exhaustive or indicative of Stemline Therapeutics, Inc.'s endorsement or financial support. There may be other foundation support available to patients.

Personalized Support and Care Throughout Your Treatment Journey

Our Nurse Advocates are here to help support you as you begin your treatment journey. Every Nurse Advocate is oncology certified and will provide personalized education, helpful tools, and resources.



What to expect from your Nurse Advocate



Before treatment starts, you will receive several calls from your Nurse Advocate to go over support services including financial assistance, education, confirmation of your first treatment appointment, and review of your insurance coverage.



During treatment cycles, your Nurse Advocate will call with treatment updates, reminders, and additional education.



Following each treatment cycle, your Nurse Advocate will call to check in with you and provide additional guidance, including support to help you transition from inpatient to outpatient treatment, when applicable.

After treatment has been completed for 30 days, your Nurse Advocate will make a follow-up call to provide additional education, guidance, and resources.

Dedicated Nurse Advocates are available to provide education and answer questions about treatment with ELZONRIS Injection for IV Use. Nurse Advocate support is not intended to replace discussions between you and your healthcare provider.

If you have any questions or concerns before, during, or after treatment cycles, Nurse Advocates are available to take your call Monday - Friday, from 9:00 AM to 6:00 PM EST at 1-833-4-STEMLINE (1-833-478-3654)



Enrolling in Stemline ARC Is Simple

Together with your doctor, follow these simple steps to enroll in Stemline ARC:



Fill out the enrollment form with your doctor.



Together with your doctor, sign and date Stemline ARC enrollment form authorizations, certifications, and consent fields.



Provide your doctor with all required documentation.



Your doctor will send all required documentation to Stemline ARC.

- Your Nurse Advocate will call you within 1 business day of enrollment

Enrollment Reminders

Please use the checklist below to ensure all of the required documentation is included:

- ✓ **Sign all necessary forms provided to you by your doctor**
- ✓ **Your doctor will let you know if you need to provide your most recent W2, 1099, or other proof of income**
- ✓ **Copy both sides of your insurance card(s) and give them to your doctor**

For questions or more information about Stemline ARC, call 1-833-4-STEMLINE (1-833-478-3654) from 9:00 AM to 6:00 PM EST, Monday through Friday.

Stemline Commercial Co-Pay Program Terms and Conditions

By using the Stemline Commercial Co-Pay Program, the patient acknowledges and confirms that, at the time of usage, (s)he is currently eligible and meets the criteria set forth in the terms and conditions described. The Stemline Commercial Co-Pay Program is valid ONLY for patients with commercial (private or nongovernmental) insurance who are taking the medication for an FDA-approved indication. Patients using Medicare, Medicaid, or any other federal or state government-funded program to pay for their medications are not eligible. Patients who start utilizing their government coverage during their enrollment period will no longer be eligible for the program. Patients may pay as little as \$0 per month and Stemline Therapeutics, Inc. will pay the remaining out-of-pocket cost up to a maximum of \$25,000 per calendar year. Any costs exceeding the maximum of \$25,000 are the responsibility of the patient. This Commercial Co-Pay Program is not health insurance or a benefit plan. Distribution or use of the Stemline Commercial Co-Pay Program does not obligate use or continuing use of any specific product or provider. Patient or guardian is responsible for reporting the receipt of all Commercial Co-Pay Program benefits or reimbursement received to any insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the Commercial Co-Pay Program, as may be required. The Commercial Co-Pay Program is not valid for medications the patient receives for free or that are eligible to be reimbursed by private insurance plans or other healthcare or pharmaceutical assistance programs that reimburse the patient in part or for the entire cost of his/her Stemline medication. Patient, guardian, pharmacist, prescriber, and any other person using the Commercial Co-Pay Program agree not to seek reimbursement for all or any part of the benefit received by the recipient through the offer.

The Stemline Commercial Co-Pay Program will be accepted by participating pharmacies, physician offices, or hospitals. To qualify for the benefits of this Commercial Co-Pay Program, the patient may be required to pay out-of-pocket expenses for each treatment. This Commercial Co-Pay Program is only available with a valid prescription and cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription. Use of this Commercial Co-Pay Program must be consistent with all relevant health insurance requirements and payer agreements. Participating patients, pharmacies, physician offices, and hospitals are obligated to inform third-party payers about the use of the Commercial Co-Pay Program as provided for under the applicable insurance or as otherwise required by contract or law. ELZONRIS Injection for IV Use provided by the Commercial Co-Pay Program may not be sold, purchased, traded, or offered for sale, purchase, or trade. Program eligibility period is contingent upon the patient's ability to meet and maintain all requirements as set forth by the program. Stemline Therapeutics, Inc. may periodically verify eligibility and will terminate patients without obligation to pay claims if change to status is detected. This program is not valid where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents where applicable (eg, MA, CA). The patient must be 18 years or older to receive Commercial Co-Pay Program assistance. Assistance provided by the Commercial Co-Pay Program is (1) void where prohibited by law; (2) only valid in the United States and Puerto Rico; (3) only valid for FDA-approved on-label indications of Stemline products; and (4) expires at the end of the calendar year. Healthcare providers may not advertise or otherwise use the program as a means of promoting their services or Stemline Therapeutics, Inc. products to patients. Stemline Therapeutics, Inc. reserves the right to rescind, revoke, amend, or terminate the program without notice at any time.



Visit [StemlineARC.com](https://www.stemlinearc.com) for more information

IMPORTANT SAFETY INFORMATION (cont'd)

- **Hypersensitivity reactions** may occur with ELZONRIS. Symptoms may include rash, itching (pruritus), wheezing, or swelling in your face, including around your eyes and/or in and around your mouth
- **Liver damage** is usually detected through blood tests. Symptoms may include feeling tired (fatigue), loss of appetite, yellowing of your skin or the whites of your eyes (jaundice), or upper right abdominal pain or discomfort

Your healthcare provider will periodically test your blood while you are on ELZONRIS to check for liver damage.

Contact your healthcare provider immediately if you have any of these symptoms.

Getting medical treatment right away may help keep these problems from becoming more serious.

If you have any side effects during treatment with ELZONRIS, your healthcare provider may hold your treatment for a period of time or completely stop your treatment with ELZONRIS.

The most common side effects of ELZONRIS include CLS, nausea, feeling tired (fatigue), swelling in your legs or feet, fever, and weight gain.

These are not all of the possible side effects of ELZONRIS. If any new side effects start or an existing one gets worse, contact your healthcare provider immediately. For more information, talk to your treatment team.

Be sure to tell your treatment team about:

- all of your medical conditions, including if you
 - are pregnant or plan to become pregnant. ELZONRIS may harm your unborn baby
 - If you are a female who can become pregnant, you should use effective birth control during ELZONRIS treatment and for at least 1 week after the last dose
 - Tell your healthcare provider right away if you become pregnant during treatment with ELZONRIS
 - are breastfeeding or plan to breastfeed. It is not known if ELZONRIS passes into breast milk. You and your healthcare provider should decide if you will receive ELZONRIS or breastfeed. You should not do both
- all of the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements

You can report any side effects to Stemline Therapeutics, Inc. at 1-877-332-7961 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for ELZONRIS, including Boxed WARNING, to learn more.

